Clinical Trial Update: A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of BBI503 in adults with advanced hepatobiliary cancer (hepatocellular carcinoma and cholangiocarcinoma) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Hepatocellular Carcinoma

Drugs mentioned

• BBI503

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Hepatocellular Carcinoma, Cholangiocarcinoma | Phase 2 | Status: COMPLETED